Influenza virus vaccine

Inactivated trivalent influenza virus vaccine (annual) 0.5 mL intramuscularly (Bll)... 

Kiecolt-Glaser, J.K. et al., Chronic stress alters the immune response to influenza virus vaccine in older adults, Proc. Natl. Acad. Sci. U.S.A., 93, 3043, 1996. 

Viral vaccines are cultivated on inanimate media. Some examples include hepatitis b vaccine, influenza virus vaccine, measles virus vaccine, rabies vaccine, rubella vaccine, and yellow fever vaccine. The viral vaccines are available as lyophilized powder for reconstitution, or suspension for injections,... 

In April 2007, the FDA approved the FI5N1 Influenza Virus Vaccine, which consists of the hemagglutinin (HA) of the virus strain AJ Vietnam/1203/2004 (clade 1) in the presence of porcine gelatin (a stabilizer) and a mercury derivative, Thimerosal (a preservative). 

Agents that may increase theophylline levels include allopurinol, beta blockers (nonselective), calcium channel blockers, cimetidine, oral contraceptives, corticosteroids, disulfiram, ephedrine, influenza virus vaccine, interferon, macrolides, mexiletine, quinolones, thiabendazole, thyroid hormones, carbamazepine, isoniazid, and loop diuretics. 

Influenza Virus Vaccine, Live, Intranasal (FluMist)... 

Moldoveanu, Z., Love-Homan, L., Huang, W.Q. and Krieg, A.M. (1998) CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine, 16, 1216-1224. 

Influenza virus Influenza Research University of Texas Southwestern Medical Center Database Comprehensive, integrated data about influenza virus genome sequences, virus phenotypic characteristics, and results from surveillance activities for the discovery and development of influenza virus vaccines, diagnostics, and therapeutics (http //www.fludb.org/brc/home. do decorator=influenza)... 

Influenza virus vaccine live intranasal-medimmune vaccines CATV-T, influenza vaccine live intranasal. Dmgs R D 2003, 4 (5), 312-319. 

Minutello M, Senatore F, CecchineUi G, Bianchi M, Andreani T, Podda A, Crovari P. Safety and immunogeni-city of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999 17(2) 99-104. 

Meredith CG, Christian CD, Johnson RF, Troxell R, Davis GL, Schenker S. Effects of influenza virus vaccine on hepatic drug metabolism. Clin Pharmacol Ther 198537(4) 396-401. 

Figure 19-4 Reactogenicity of commercial vaccines in the PTE module and by monocytes alone. Vaccines hepatitis B virus (FIBV 1 200), influenza virus vaccine (Fluzone 1 400), and tetanus toxoid vaccine (DTaP 1 200) were used in the study. PTE is the peripheral tissue equivalent module containing CD33+ positively selected cells (left). CD33+ monocytes alone do not produce any appreciable cytokines nor chemokines when stimulated with the vaccines (right).

Clinicians administering vaccines covered by the NCVIA are protected against litigation surrounding possible vaccine-related adverse events.Pharmacists are commonly involved with the administration of pneumococcal 23-valent and influenza virus vaccines—vaccines not currently covered by the NCVIA. Despite this, pharmacists should be familiar with this far-reaching legislation and understand both the ramifications and limitations on vaccine coverage. 

The Advisory Committee on Immunization Practices (ACIP) makes yearly recommendations concerning the use and composition of influenza virus vaccine. These are published in Morbidity and Mortality Weekly Report annually. The reader should refer to these annual guidelines as a supplemental update to this chapter. 

Medimmune Vaccines I. Influenza virus vaccine hve, intranasal FluMist 2003-2004 Formula. Package Insert 2003 1—19. 

Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998 338 1405-1412. 

Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults A randomized, controlled trial. JAMA 1999 282 137-144. 

Minutello, M., F. Senatore, G. CecchineJJi, M. Bianchi, T. Andreani, A. Podda, and P. Crovari (1999) Safety and immunogenicity of an inactivated subunit influenza virus vaccine com-... 

INFLUENZA VIRUS VACCINE, TRIVALENT TYPES A B (SPLIT VIRUS)... 

---